D3 Bio is a biotechnology company dedicated to the discovery, development, and registration of innovative medicines in oncology and immunology. The company aims to address existing gaps in conventional treatments by utilizing clinical and market data to identify areas for improvement. D3 Bio employs unique drug development methodologies that target new diseases and delivery methods, ultimately providing patients with alternative therapeutic options in these critical areas of healthcare.
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.
MegaRobo is an AI and robotics company based in Beijing, China, that focuses on automating life science research and clinical diagnosis. Founded in 2016, the company develops collaborative robots and advanced automation solutions tailored for life science companies and scientific research institutions. By integrating robotics and artificial intelligence technology into practical applications, MegaRobo aims to enhance research efficiency and provide innovative laboratory services. Its commitment to the life sciences sector positions it as a key player in the advancement of intelligent automation in scientific research.
Engine Biosciences is a biotech company focused on revolutionizing drug discovery through the application of machine learning and network biomedicine. Based in San Francisco and Asia, the company has developed a proprietary platform that combines high-throughput wet lab experimentation with advanced artificial intelligence algorithms. This platform is designed to map and analyze complex biological networks, generating unique data on gene interactions and providing insights validated through controlled experiments. By doing so, Engine Biosciences aims to accelerate research and development processes and reduce costs associated with creating new medical therapies. The company collaborates with various partners and actively applies its technology to address a range of disease indications, leveraging the expertise of its scientific leadership team, which includes faculty members from renowned institutions such as MIT, Harvard, and the Mayo Clinic.
Oxford Genetics Ltd. is a UK-based biotechnology company that specializes in synthetic biology, focusing on DNA design, protein expression optimization, and cell line development technologies and services. The company offers a variety of plasmid products, including CRISPR plasmids, reporter genes, and viral vectors, which are used for various research and production applications. All products are designed to be free of intellectual property restrictions. Oxford Genetics provides its offerings through a global distribution network, serving customers in countries such as the United States, Canada, Germany, and Japan, while also enabling online purchases. Founded in 2011 and headquartered in Begbroke, the company has established a strategic partnership with The Native Antigen Company Ltd. to enhance its capabilities in the biotechnology sector.
AnchorDx, also known as Guangzhou Baseline Medical, specializes in high-throughput sequencing technologies and molecular liquid biopsies, offering non-invasive access to genetic information. The company focuses on precision medicine and aims to be a leading global provider of medical solutions by leveraging its expertise in cancer genomics, genetics, and bioinformatics. With a core team possessing over 20 years of industry experience, AnchorDx collaborates with various downstream enterprises, hospitals, and research institutions to create an integrated industrial chain that facilitates the transformation of academic research into clinical products. The company is committed to developing independent intellectual property rights and competitive clinical testing products, thereby providing accurate and comprehensive services to patients, doctors, and medical institutions.
Drug Farm Inc. is a biotechnology company based in Shanghai, China, specializing in the development of innovative treatments for metabolic diseases, infections, and autoimmune disorders. The company utilizes a unique platform known as IDInVivo, which integrates advanced genetic screening and artificial intelligence technologies to identify novel drug targets and expedite the drug development process. By leveraging these cutting-edge methodologies, Drug Farm aims to create first-in-class therapies that address conditions such as obesity, diabetes, hepatitis B virus (HBV), and cancer. Their approach combines insights from living animals with intact immune systems and sophisticated AI techniques, including supervised, active, and reinforcement learning, to enhance the efficiency of medicinal chemistry and improve healthcare outcomes.
D3 Bio is a biotechnology company dedicated to the discovery, development, and registration of innovative medicines in oncology and immunology. The company aims to address existing gaps in conventional treatments by utilizing clinical and market data to identify areas for improvement. D3 Bio employs unique drug development methodologies that target new diseases and delivery methods, ultimately providing patients with alternative therapeutic options in these critical areas of healthcare.
JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in developing, manufacturing, and promoting cell-based immunotherapies aimed at treating cancer. The company leverages advanced technologies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, to enhance the body's immune response against cancer. JW Therapeutics focuses on addressing both hematological cancers and solid tumors, with its leading product candidate being relmacabtagene autoleucel, designed as a potential superior anti-CD19 CAR-T therapy. The company's mission is to improve patient outcomes and quality of life for those battling cancer through innovative treatment solutions.
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.
Mediscope is an innovative platform focused on addressing the challenges of social isolation and its detrimental effects on mental and physical health. By leveraging evidence-based peer support and benefits navigation, Mediscope aims to enhance health outcomes and reduce medical costs. The platform facilitates meaningful connections among users, allowing them to share experiences and gain insights from individuals who have faced similar challenges. Through its AI-powered features, Mediscope empowers individuals to navigate their health journeys more effectively, promoting engagement and community support to combat loneliness and foster well-being.
HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.
Huimei Technology is a National high-tech enterprise that offers medical artificial intelligence solutions.
Pharmapace, Inc. is a clinical research services provider based in San Diego, California, established in 2013. The company specializes in offering a comprehensive range of biometrics services to support all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, project management, and medical writing. By focusing on delivering high-quality consulting and outsourcing services, Pharmapace aims to assist biotechnology and pharmaceutical companies in their drug development programs and ensure effective project execution aligned with clients' goals and financial needs. Since May 2019, Pharmapace has operated as a subsidiary of WuXi Clinical.
Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.
PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, making healthcare more accessible. The platform also allows patients to order laboratory tests that can be conducted at home. Additionally, HaloDoc helps users locate the nearest hospitals and clinics, streamlining the process of obtaining medical advice and services in real-time.
Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.
Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.
Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.
JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in developing, manufacturing, and promoting cell-based immunotherapies aimed at treating cancer. The company leverages advanced technologies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, to enhance the body's immune response against cancer. JW Therapeutics focuses on addressing both hematological cancers and solid tumors, with its leading product candidate being relmacabtagene autoleucel, designed as a potential superior anti-CD19 CAR-T therapy. The company's mission is to improve patient outcomes and quality of life for those battling cancer through innovative treatment solutions.
Engine Biosciences is a biotech company focused on revolutionizing drug discovery through the application of machine learning and network biomedicine. Based in San Francisco and Asia, the company has developed a proprietary platform that combines high-throughput wet lab experimentation with advanced artificial intelligence algorithms. This platform is designed to map and analyze complex biological networks, generating unique data on gene interactions and providing insights validated through controlled experiments. By doing so, Engine Biosciences aims to accelerate research and development processes and reduce costs associated with creating new medical therapies. The company collaborates with various partners and actively applies its technology to address a range of disease indications, leveraging the expertise of its scientific leadership team, which includes faculty members from renowned institutions such as MIT, Harvard, and the Mayo Clinic.
AnchorDx, also known as Guangzhou Baseline Medical, specializes in high-throughput sequencing technologies and molecular liquid biopsies, offering non-invasive access to genetic information. The company focuses on precision medicine and aims to be a leading global provider of medical solutions by leveraging its expertise in cancer genomics, genetics, and bioinformatics. With a core team possessing over 20 years of industry experience, AnchorDx collaborates with various downstream enterprises, hospitals, and research institutions to create an integrated industrial chain that facilitates the transformation of academic research into clinical products. The company is committed to developing independent intellectual property rights and competitive clinical testing products, thereby providing accurate and comprehensive services to patients, doctors, and medical institutions.
ResearchPoint Global is a full-service contract clinical research organization that operates in over 60 countries. The company specializes in providing a comprehensive range of services for clinical trials, which include project management, site selection and management, safety and medical monitoring, clinical monitoring, data management, and biostatistics. ResearchPoint Global supports the pharmaceutical, medical device, and biotechnology industries by offering expertise across all phases of clinical development, including multi-regional clinical trials. With a team of experienced professionals, the organization is known for its agility and ability to adapt to the specific needs of its clients.
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.
HD Biosciences Inc. (HDB) is a Shanghai-based biotech company specializing in drug discovery contract research. HDB has developed extensive knowledge and comprehensive technology platforms for drug discovery including assay development, high throughput drug screening, SAR, closed-loop and hit-to-lead biology solutions, as well as natural product-based lead discovery. The Company has signed multiple-year research agreements with clients including Pfizer, Organon and other pharmaceutical and biotech clients and is an indisputable leader in high value-added biology-based drug discovery CRO business in China.
ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.
Strateos is a company that specializes in automating laboratory processes in chemistry, biology, and tissue analysis through its advanced robotic cloud laboratory platform. By integrating cutting-edge robotics with sophisticated software for imaging and analytics, Strateos provides pharmaceutical partners with the tools to accelerate drug discovery and development. The company emerged from a merger between Transcriptic, which pioneered on-demand robotic lab services, and 3Scan, known for its automation and machine learning capabilities in tissue analysis. Strateos aims to streamline the drug discovery process by offering a comprehensive suite of technologies that transform life science methods into data-driven solutions. This approach not only enhances productivity and efficiency but also redefines the traditional research model, making it more accessible and effective for scientists. Through its innovative platform, Strateos positions itself as a valuable partner in the life sciences sector, focusing on delivering significant time and cost savings in the drug development process.
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
CRELUX is a global leader for structure based drug discovery solutions. Working for pharma, biotech and research organizations our products and services are highly individualized for their customers. Your discovery projects deserve to receive the best possible support – talk to the experts! Their have been delivering customized and integrated solutions in drug discovery, X-ray crystallography, protein supply, biophysical analysis and screening for more than a decade. Their mission is to enable their clients to perform their work better, faster, more efficiently and more successfully.
Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York that focuses on discovering and developing therapies targeting phosphoinositide (PI) signaling pathways. Established in 2015, the company aims to create novel small molecules that address serious medical conditions, particularly cancer and metabolic diseases. By honing in on unique enzyme targets involved in critical cellular processes such as cell division, growth, trafficking, and signaling, Petra Pharma seeks to develop innovative treatments that can enhance human health and provide new options for healthcare providers.
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
TruTag Technologies, Inc. specializes in precision-fabricated nano-porous silica for applications in drug delivery, product authentication, and data intelligence. The company has developed TruTag, an edible microtag that enables the identification and quality assurance of various products, including medicines, food items, and consumer goods. This technology is instrumental in combating counterfeiting, managing product diversions, and enhancing quality control across industries such as healthcare, life sciences, and food and beverages. TruTag Technologies operates a state-of-the-art cGMP manufacturing facility in Hawaii and maintains engineering and business development offices in California, Pennsylvania, Florida, Massachusetts, and Scotland. The company has been recognized for its innovative contributions, receiving accolades from organizations such as the SPIE Prism Awards and the World Economic Forum.
ALDEA Pharmaceuticals, Inc. is focused on developing small-molecule modulators of the aldehyde dehydrogenase (ALDH) enzyme family to address diseases related to toxic aldehyde accumulation. The company’s innovative technology aims to provide new treatment options across various therapeutic areas, particularly for conditions associated with aldehyde metabolism dysfunction, such as acute alcohol toxicity and rare diseases like Fanconi anemia. One of the key compounds being developed enhances the detoxification of acetaldehyde, which may alleviate acute symptoms and mitigate long-term tissue damage and cancer risk. Founded in 2008 and based in Redwood City, California, ALDEA Pharmaceuticals is working to advance its proprietary solutions to tackle unmet medical needs.
TruTag Technologies, Inc. specializes in precision-fabricated nano-porous silica for applications in drug delivery, product authentication, and data intelligence. The company has developed TruTag, an edible microtag that enables the identification and quality assurance of various products, including medicines, food items, and consumer goods. This technology is instrumental in combating counterfeiting, managing product diversions, and enhancing quality control across industries such as healthcare, life sciences, and food and beverages. TruTag Technologies operates a state-of-the-art cGMP manufacturing facility in Hawaii and maintains engineering and business development offices in California, Pennsylvania, Florida, Massachusetts, and Scotland. The company has been recognized for its innovative contributions, receiving accolades from organizations such as the SPIE Prism Awards and the World Economic Forum.
Avelas Biosciences is focused on enhancing cancer surgery through innovative intraoperative imaging technology. The company's proprietary platform employs activatable cell-penetrating peptides to facilitate real-time diagnosis of metastatic nodes during surgical procedures. This advancement allows oncologic surgeons to create a luminous map of the surgical site, which helps in identifying critical areas and improving surgical precision. By providing this real-time information, Avelas aims to reduce the likelihood of repeat surgeries and ultimately improve patient outcomes, setting a new standard of care in the field of oncology.